Descriptive characteristics of males with duchenne muscular dystrophy in those covered by government (Medicaid) and non-government (private) health plans

Abstract

Disclosures: Oscar H Mayer is a paid consultant for Santhera Pharmaceuticals. John Karafilidis is an employee of Santhera Pharmaceuticals. Kate Higgins and Brian Griffin are employees of Truven Health Analytics, an IBM company. Review Process: Double-blind peer review. Compliance with Ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors. Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original authors and source are given appropriate credit. © The Authors 2018.